Inactive Instrument

Samsara Vision, Inc. Stock

Equities

SMSA

US79600A1051

Medical Equipment, Supplies & Distribution

Dynamic Chart
Samsara Vision Announces First U.S. Surgeries of the Sing Imt, for Age-Related Macular Degeneration as Part of the Concerto Study CI
Samsara Vision and Lansheng Medical “Myvision” Announce Collaboration to Commercialize the Sing Imt™ in China CI
Samsara Vision, Inc. to Initiate A U.S. Pma Supplemental Study of the Sing Imt™, A New-Generation Technology for Age-Related Macular Degeneration CI
Samsara Vision, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Samsara Vision, Inc. Auditor Raises 'Going Concern' Doubt CI
Samsara Vision, Inc. Announces the First Three Successful Clinical Cases in Italy Using Its Sing Imt™ CI
Samsara Vision, Inc. has filed an IPO. CI
Samsara Vision, Inc. Auditor Raises 'Going Concern' Doubt CI
VisionCare Ophthalmic Technologies, Inc. Announces Appointment of Thierry Clidiere to Board of Directors CI
VisionCare Ophthalmic Technologies Announces Executive Appointments CI
Visioncare Ophthalmic Technologies Announces Executive Changes CI
VisionCare Ophthalmic Technologies, Inc. announced that it has received funding CI
VisionCare Ophthalmic Technologies, Inc. Announces Board Changes CI
VisionCare Ophthalmic Technologies, Inc. Announces Management Promotions CI
VisionCare Ophthalmic Technologies, Inc. Secures Up to $15 Million to Accelerate Growth of its Novel Treatment for Age-Related Macular Degeneration CI
More news
Managers TitleAgeSince
Chief Executive Officer 46 20-07-05
Director of Finance/CFO 53 20-12-31
Chief Tech/Sci/R&D Officer - 22-10-31
Members of the board TitleAgeSince
Director/Board Member 55 15-09-30
Director/Board Member 51 21-01-03
Director/Board Member 54 21-01-03
More insiders
Samsara Vision, Inc is a specialty medical device company. The Company is involved in bringing vision and freedom back to patients suffering from late-stage conditions of the retina. It is engaged in the research, development, manufacturing, and marketing of ophthalmic devices and technologies that are intended to improve vision and quality of life for individuals with untreatable retinal disorders, particularly Age-Related Macular Degeneration (AMD). Its product line consists of its first-generation implantable miniature telescope (IMT), which it refers to as WA IMT; its Smaller-Incision, New Generation (SING) IMT, which it refers to as SING IMT; and its Tsert delivery system. Its WA IMT is the implantable medical device that works similarly to the telephoto lens of a camera, which enables improvement in vision and quality of life for individuals with the most advanced form of AMD, commonly referred to as late-stage AMD.
More about the company